+

WO2002006341A1 - Facteur tropique capable de produire un effet salutaire sur le systeme nerveux chez un sujet - Google Patents

Facteur tropique capable de produire un effet salutaire sur le systeme nerveux chez un sujet Download PDF

Info

Publication number
WO2002006341A1
WO2002006341A1 PCT/US2001/022315 US0122315W WO0206341A1 WO 2002006341 A1 WO2002006341 A1 WO 2002006341A1 US 0122315 W US0122315 W US 0122315W WO 0206341 A1 WO0206341 A1 WO 0206341A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
neurotrophic factor
pharmaceutically acceptable
factor
cells
Prior art date
Application number
PCT/US2001/022315
Other languages
English (en)
Inventor
Larry I. Benowitz
Carleen A. Irwin
Paul Jackson
Original Assignee
Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Medical Center Corporation filed Critical Children's Medical Center Corporation
Priority to AU2001280566A priority Critical patent/AU2001280566A1/en
Publication of WO2002006341A1 publication Critical patent/WO2002006341A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention provides an isolated neurotrophic factor of the type that is present in medium in which Schwann cells have been cultured, that stimulates axonal outgrowth of naive goldfish retinal ganglion cells, that stimulates axonal outgrowth of embryonic rat spinal cord neurons, and that passes through a centrifugal filter with a 1 KDa cut-off.
  • the invention further provides a neurotrophic factor that fails to bind to a Cl 8 reversed-phase HPLC column, that forms a compound that elutes from a reverse-phase HPLC column at 23 minutes, after being chemically derivatized with AQC, and that has an elution time of 6 minutes on a GlO-Sepharose size-exclusive column.
  • the neurotrophic factor is AF-1, or an analog or derivative or AF-1.
  • the neurotrophic factor can be mammalian, human, bovine, rat, or can be derived from other types of vertebrates or invertebrates.
  • the invention provides methods for treating neurological conditions that include administering to a subject a therapeutically effective amount of a neurotrophic factor or composition comprising AF-1, thereby producing a neurosalutary effect in the subject.
  • a "neurosalutary effect” means a response or result favorable to the health or function of a neuron, of a part of the nervous system, or of the nervous system generally.
  • the neurotrophic factor such as AF-1
  • AF-1 is administered to a subject in accordance with the present invention such that the factor is brought into contact with neurons of the central nervous system of the subject.
  • AF-1 may be administered into the cerebrospinal fluid of the subject into the intrathecal space by introducing the factor into a cerebral ventricle, the lumbar area, or the cisterna magna.
  • the AF-1 can be administered locally to cortical neurons or retinal ganglion cells to produce a neurosalutary effect.
  • the pharmaceutically acceptable formulation provides sustained delivery, providing effective amounts of the neurotrophic factor to a subject for at least one week, or in other embodiments, at least one month, after the pharmaceutically acceptable formulation is initially administered to the subject.
  • Approaches for achieving sustained delivery of a formulation of the invention include the use of a slow release polymeric capsule, a bioerodible matrix, or an infusion pump that disperses the factor or other therapeutic compound of the invention.
  • the infusion pump may be implanted subcutaneously, intracranially, or in other locations as would be medically desirable.
  • the therapeutic factors or compositions of the invention would be dispensed by the infusion pump via a catheter either into the cerebrospinal fluid, or to a site where local delivery was desired, such as a site of neuronal injury or a site of neurodegenerative changes.
  • the present invention features a method that includes administering to a subject a therapeutically effective amount of a neurotrophic factor in combination with a therapeutically effective amount of a macrophage-derived factor and/or a cAMP modulator, thereby producing a neurosalutary effect in the subject.
  • compositions that include an AF-1 neurotrophic factor and a pharmaceutically acceptable carrier may be packed with instructions for use of the pharmaceutical composition for producing a neurosalutary effect in a subject.
  • the pharmaceutical composition may further include a cAMP modulator and/or a macrophage-derived factor, such as oncomodulin or TGF- ⁇ .
  • Figure la is a histogram of the quantitation of neurite outgrowth: axon length distribution was measured five days after nerve cells were cultured with conditioned medium at the indicated concentrations of 0%, 5%, 10% and 15%. Number of cells extending processes l-five'cell diameter in length (light shading); number extending processes greater than five cell diameters in length (dark shading). Values represent averages from 4 wells for each conditioned medium concentration; error bars show + standard error of the mean (SEM).
  • Figure lb is a graph with dose-response curves of 2 separate experiments showing neurite outgrowth (% cells with axons greater than five cell diameters) in response to increasing concentrations of conditioned medium (0%, 5%, 10%, and 15%).
  • Figure lc is a graph of cell survival as a function of conditioned medium concentration in two independent experiments (5,6-CFDA labeled cells counted in 14 successive microscope fields, averaged for 4 wells, normalized by L-15 control values).
  • Figures 2a and 2b are graphs of neurite-promoting activity versus size fractions of conditioned medium.
  • Figure 2a is conditioned medium obtained from previously intact optic nerves (day O) or from optic nerves that had been injured 3 or 7 days previously, separated into high and low molecular weight fractions by ultrafiltration (3,000 Da cut-off). In all cases, both low (light shading) and high (dark shading) molecular weight fractions yielded high levels of neurite-promoting activity.
  • Figure 2b compares control with conditioned medium and conditioned medium separated with a molecular weight cut-off of 1,000 Da.
  • Figure 2c is a chromatogram of the high molecular weight fraction of conditioned medium separated by size-exclusion high performance liquid chromatography (optical density, O.D., read at 280 nm). The high molecular weight fraction was concentrated 70-fold and then separated into 1 ml fractions (numbered bars). Arrows indicate the retention times of the molecular weight calibration standards (BSA, bovine serum albumin; Ova, ovalbumin; Cyto C, cytochrome C).
  • Figure 2d is a graph of neurite outgrowth in response to column fractions assayed at concentrations of 25% (calculated on the basis of the starting material). Fractions were first bioassayed in pairs; if any activity was seen, they were retested individually, and otherwise they were retested in pairs. Only fractions 12 and 13 contained significant neurite-promoting activity.
  • Figure 3 is a graph of neurite outgrowth showing that the low molecular weight factor, AF-1, can be isolated using a two-phase solvent extraction system.
  • the negative control is culture medium alone.
  • the positive control, lane 2 consists of the low molecular weight (MW less than 3,000 Da) fractions of the molecules secreted by the glial sheath cells into culture medium that induce high levels of regenerative changes in the test cell cultures.
  • this material is mixed with an organic solvent at pH 7.5, isobutanol, little activity remains in the aqueous phase (pH 7.5 Aq).
  • FIG. 4 is a graph of neurite outgrowth showing that when the partially purified extract containing the low molecular weight trophic factor, AF-1, is separated by reversed faze HPLC, the active component appears in particular column fractions (FC, FD, FE).
  • the negative control L-15
  • the positive control is the unfractionated low molecular weight component of the molecules secreted by optic nerve glia (conditioned medium less than 3,000 Da, 10%) concentration); FA-FI indicate column fractions from the high performance liquid chromatography separation.
  • Figure 5 A depicts the elution profile obtained after the separation of a bovine vitreous fluid sample on a normal-phase LC-NH 2 column.
  • Figure 5B is a graph depicting the results from the analysis of the elution fractions (from the normal-phase LC-NH 2 column) using an axonal growth assay.
  • axogenesis factor 1 is a small, heat-stable, protease-sensitive molecule that passes through a 1 kDa cut-off filter
  • AF-2 is a heat-labile protein with an estimated size of 8-15 kDa.
  • Outgrowth was scored blind in 3 to 6 wells per condition based on the fraction of large, viable cells extending neurites greater than or equal to five cell diameter after 5 days in culture, with viability assessed using 5(6)-carboxyfluorescein diacetate.
  • a second, distinct peak of neurite-promoting activity has a M r of less than 1 kDa.
  • AF-1 does not seem to coincide with any of the molecules identified previously in conditioned medium from the goldfish optic nerve.
  • Mizrachi et al. (1986) described a 10 kDa protein in optic nerve conditioned medium that binds to DEAE at neutral pH and that is adsorbed onto polylysine substrate. This protein enhanced neurite outgrowth in retinal explants that had begun to regenerate their axons in vivo, but did not induce outgrowth from unprimed retinas.
  • Other components of conditioned medium that also differ from the ones described here include apolipoprotein A, a 28 kDa protein that binds to heparin sulfate proteoglycans and that may contribute to lipid transport (Harel et al.
  • conditioned medium contains an active component, AF-1, that passes through a 1 kDa cut-off filter. It is heat resistant but sensitive to proteinase K digestion. AF-1 is considerably more concentrated in conditioned medium than in optic nerve homogenates, suggesting that it is actively secreted.
  • AF-1 induces vigorous neurite outgrowth from RGCs regardless of whether the regenerative response had been initiated in vivo by a priming lesion. Moreover, ganglion cells primed to grow by a conditioning lesion show essentially no outgrowth in the absence of AF-1. Thus, under the experimental conditions used herein, AF-1 is required to induce and maintain axonal regeneration.
  • the goldfish optic nerve consists of several cell types, including oligodendroglia, astrocytes, macrophages, microglia, and epithelial cells (Battisti et al, 1992).
  • the trophic factors could be secreted from any of these or, alternatively, they might only be released from the cytoplasm of cells injured by nerve crush or by dissection in culture.
  • concentration of AF-1 in conditioned media and in cytosol fractions prepared from optic nerve homogenates was compared. AF-1 was found to be present in significantly higher concentrations in conditioned medium than in optic nerve cytosol, suggesting that it is actively secreted.
  • media containing factors secreted from dissociated goldfish optic nerve glia contains appreciable levels of a trophic factor of less than 3,000 Da, and lower levels of one greater than 3,000 Da.
  • AF-1 was initially characterized by determination of the presence of trophic activity after passage of material through molecular weight filters or sieves of specific molecular weight. Several methods were used to determine the size of the active factor. Conditioned medium was first separated by centrifugal ultrafiltration using filters with molecular weight cut-offs of 10, 100, and 1000 kDa. Filtrates and retentates were tested in the bioassay. Next, conditioned medium was passed through a 6,000 Da desalting column and fractions were monitored by absorbance at 280 nm (for protein) and by measuring conductivity (for low-molecular weight fractions containing salts). Fractions containing high and low molecular weight constituents were evaluated by bioassay and were both found to be active.
  • Fractions greater than 6,000 Da were pooled, concentrated 10- to 100-fold using a filter with a 3,000 Da cut-off, then separated by high performance liquid chromatography (HPLC).
  • HPLC high performance liquid chromatography
  • Anion-exchange chromatography of the trophic factor for example, on diethylaminoethyl cellulose columns, was then carried out.
  • the column was initially washed with 25 mM HEPES, and then stepwise eluted with 0.1, 0.2, 0.5 and 1.0 M NaCl in 25 mM HEPES.
  • AF-1 various means of producing purified AF- 1 compound are available.
  • the compound may be isolated from tissue or cell culture sources, or may be produced by synthetic means. These methods are known to those skilled in the art. These methods can be used to synthesize either AF-1 as characterized herein, or additionally compounds having AF-1 as a component of a larger chemical structure. Such compounds may be readily synthesize to produce compounds that will have desired characteristics of stability, pharmacokinetics, or other characteristics pertinent to medical uses.
  • the compounds can be screened for activity as described above and in the following sections.
  • AF-1 will act upon other populations of neurons besides the retinal ganglion cells, including both central nervous structures such as the spinal cord and cerebral cortex, as well as peripheral nervous system components such as motor and sensory neurons.
  • central nervous structures such as the spinal cord and cerebral cortex
  • peripheral nervous system components such as motor and sensory neurons.
  • AF-1 for example, a mammalian spinal cord injury model.
  • the spinal cord is transected through the dorsal columns, after which AF-1 is delivered either through the use of a minipump or by embedding in slow-release capsules, as described in more detail below.
  • AF-1 compositions can be used not only in the treatment of patients as described below, but in screening assays for the identification of drugs that modulate the activity of AF-1 and in screening of patient samples for the presence of a functional neurotrophic factor. Screening may be accomplished using antibodies, typically labeled with a fluorescent, radiolabeled, or enzymatic label, or by isolation of target cells and screening for binding activity, using methods known to those skilled in the art.
  • mice such as mice may be immunized by administration of an amount of immunogen effective to produce an immune response. It may be advantageous to generate antibodies to a antigen of a different species of origin than the species in which the antibodies are to be tested or utilized. The methods involved are known to those skilled in the art. Monoclonal antibody technology can be used to obtain mAbs immunoreactive with AF-1. These may be useful in the purification of the neurotrophic factor. Methods for making monoclonal antibodies are now routine for those skilled in the art. See, for example, Galfre and Milstein (1981) Meth. Enzymol. 73:3-46, incorporated herein by reference.
  • HAT-selected clones are injected into mice to produce large quantities of nxAb in ascites, that can be purified using protein A column chromatography (BioRad, Hercules, CA).
  • MAbs are selected on the basis of their (a) specificity for a particular antigen, (b) high binding affinity, (c) isotype, and (d) stability. MAbs can be screened or tested for specificity using any of a variety of standard techniques, including Western blotting or enzyme-linked immunosorbent assay (ELISA) (Koren et al. (1986) Biochim. Biophys. Acta 876:91-100).
  • the neurotrophic factor is useful as a target for identifying compounds that modulate its function, expression or activity. Accordingly, the present invention provides a method or "screening assay" for identifying modulators that have a stimulatory or inhibitory effect on the function, in vivo concentration or activity of a neurotrophic factor or of a neurotrophic factor substrate.
  • Potential modulators may be peptides, peptidomimetics, small molecules, carbohydrates, or other types of molecules.
  • the invention provides assays for screening candidate or test compounds that are reactive with, bind to or modulate the activity of a neurotrophic factor of the invention.
  • the test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel. solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one- compound' library method; and synthetic library methods using affinity chromatography selection.
  • the biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) Anticancer Drug Des. 12:145).
  • This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model.
  • an agent identified as described herein e.g., a neurotrophic factor modulating agent
  • an agent identified as described herein can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent.
  • an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent.
  • this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.
  • the ability of AF-1 or a neurotrophic factor modulator to produce a neurosalutary effect in a subject may be assessed using any of a variety of known procedures and assays.
  • the ability of AF-1 or a neurotrophic factor modulator to re-establish neural connectivity and/or function after an injury, such as a CNS injury may be determined histologically (either by slicing neuronal tissue and looking at neuronal branching, or by showing cytoplasmic transport of dyes).
  • such ability may be assessed by monitoring the ability of AF-1 to fully or partially restore the electroretinogram after damage to the neural retina or optic nerve, or to fully or partially restore a pupillary response to light in the damaged eye.
  • tests that may be used to determine the ability of a neurotrophic factor to produce a neurosalutary effect in a subject include standard tests of neurological function in human subjects or in animal models of spinal injury (such as standard reflex testing, urologic tests, urodynamic testing, tests for deep and superficial pain appreciation, proprioceptive placing of the hind limbs, ambulation, and evoked potential testing).
  • nerve impulse conduction can be measured in a subject, such as by measuring conduct action potentials, as an indication of the production of a neurosalutary effect.
  • Animal models suitable for use in the assays of the present invention include the rat model of partial transection (described in Weidner et al. (2001) Proc. Natl. Acad. Sci. USA 98:3513-3518). This animal model tests how well a compound can enhance the survival and sprouting of the intact remaining fragment of an almost fully-transected cord.
  • these animals may be evaluated for recovery of a certain function, such as how well the rats may manipulate food pellets with their forearms (to which the relevant cord had been cut 97%).
  • a certain function such as how well the rats may manipulate food pellets with their forearms (to which the relevant cord had been cut 97%).
  • Another animal model suitable for use in the assays of the present invention includes the rat model of stroke (described in Kawamata et al. (1997) Proc. Natl. Acad. Sci. USA 94(15): 8179-8184).
  • This paper describes in detail various tests that may be used to assess sensorimotor function in the limbs as well as vestibulomotor function after an injury.
  • Administration to these animals of the compounds of the invention can be used to assess whether a given compound, route of administration, or dosage provides a neurosalutary effect, such as increasing the level of function, or increasing the rate of regaining function or the degree of retention of function in the test animals.
  • Standard neurological evaluations used to assess progress in human patients after a stroke may also be used to evaluate the ability of a neurotrophic factor, e.g., AF-1 or AF-2, (alone or in combination with a macrophage-derived factor and/or a cAMP modulator) or a neurotrophic factor modulator to produce a neurosalutary effect in a subject.
  • a neurotrophic factor e.g., AF-1 or AF-2
  • a neurotrophic factor modulator e.g., AF-1 or AF-2
  • Such standard neurological evaluations are routine in the medical arts, and are described in, for example, "Guide to Clinical Neurobiology” Edited by Mohr and Gautier (Churchill Livingston Inc. 1995).
  • Electromyography records the electrical activity in muscles, and is used to assess the function of the nerves and muscles.
  • the electrode is inserted into a muscle to record its electrical activity. It records activity during the insertion, while the muscle is at rest, and while the muscle contracts.
  • the nerve conduction velocity test evaluates the health of the peripheral nerve by recording how fast an electrical impulse travels through it.
  • a peripheral nerve transmits information between the spinal cord and the muscles.
  • a number of nervous system diseases may reduce the speed of this impulse.
  • Electrodes placed on the skin detect and record the electrical signal after the impulse travels along the nerve.
  • a second stimulating electrode is sends a small electrical charge along the nerve; the time between the stimulation and response will be recorded to determine how quickly and thoroughly the impulse is sent.
  • Standard tests for function of the cranial nerves include facial nerve conduction studies; orbicularis oculi reflex studies (blink reflex studies); trigeminal-facial nerve reflex evaluation as used in focal facial nerve lesions, Bell's palsy, trigeminal neuralgia and atypical facial pain; evoked potentials assessment; visual, brainstem and auditory evoked potential measurements; thermo-diagnostic small fiber testing; and computer-assisted qualitative sensory testing.
  • the neurotrophic AF-1 of the invention may be used to produce a neurosalutary effect in a subject.
  • such methods include administering to a subject a therapeutically effective amount of a neurotrophic factor, e.g., an AF-1 factor, thereby producing a neurosalutary effect in a subject.
  • a neurotrophic factor e.g., an AF-1 factor
  • Producing a neurosalutary effect in a subject may result or aid in the treatment of a neurological disorder in a subject.
  • a “neurosalutary effect” means a response or result favorable to the health or function of a neuron, of a part of the nervous system, or of the nervous system generally. Examples of such effects include improvements in the ability of a neuron or portion of the nervous system to resist insult, to regenerate, to maintain desirable function, to grow or to survive.
  • the phrase "producing a neurosalutary effect” includes producing or effecting such a response or improvement in function or resilience within a component of the nervous system.
  • examples of producing a neurosalutary effect would include stimulating axonal outgrowth after injury to a neuron; rendering a neuron resistant to apoptosis; rendering a neuron resistant to a toxic compound such as D -amyloid, ammonia, or other neurotoxins; reversing age-related neuronal atrophy or loss of function; or reversing age-related loss of cholinergic innervation.
  • the neurotrophic factor of the invention may be administered alone or in combination with a cAMP modulator and/or a macrophage-derived factor, such as oncomodulin or TGF- ⁇ .
  • cAMP modulator includes any compound that has the ability to modulate the amount, production, concentration, activity or stability of cAMP in a cell, or to modulate the pharmacological activity of cellular cAMP.
  • cAMP modulators may act at the level of adenylate cyclase, upstream of adenylate cyclase, or downstream of adenylate cyclase, such as at the level of cAMP itself, in the signaling pathway that leads to the production of cAMP.
  • Cyclic AMP modulators may act inside the cell, for example at the level of a G-protein such as Gi, Go, Gq, Gs and Gt, or outside the cell, such as at the level of an extra-cellular receptor such as a G-protein coupled receptor.
  • a G-protein such as Gi, Go, Gq, Gs and Gt
  • an extra-cellular receptor such as a G-protein coupled receptor
  • Cyclic AMP modulators include activators of adenylate cyclase such as forskolin; non- hydrolyzable analogues of cAMP including 8-bromo-cAMP, 8-chloro-cAMP, or dibutyryl cAMP (db-cAMP); isoprotenol; vasoactive intestinal peptide; calcium ionophores; membrane depolarization; macrophage-derived factors that stimulate cAMP; agents that stimulate macrophage activation such as zymosan or IFN-D; phosphodiesterase inhibitors such as pentoxifylline and theophylline; specific phosphodiesterase IV (PDE IV) inhibitors; and beta 2-adrenoreceptor agonists such as salbutamol.
  • activators of adenylate cyclase such as forskolin
  • non- hydrolyzable analogues of cAMP including 8-bromo-cAMP, 8-chloro-cAMP, or dibutyryl
  • cAMP modulator also includes compounds that inhibit cAMP production, function, activity or stability, such as phosphodiesterases, such as cyclic nucleotide phosphodiesterase 3B.
  • cAMP modulators that inhibit cAMP production, function, activity or stability are known in the art and are described in, for example, Nano et al. (2000) Pflugers Arch 439(5): 547-54, the contents of which are incorporated herein by reference.
  • Phosphodiesterase IV inhibitor refers to an agent that inhibits the activity of the enzyme phosphodiesterase IV.
  • Examples of phosphodiesterase IV inhibitors are known in the art and include 4-arylpyrrolidinones, such as rolipram, nitraquazone, denbufylline, tibenelast, CP-80633 and quinazolinediones such as CP-77059.
  • Beta-2 adrenoreceptor agonist refers to an agent that stimulates the beta-2 adrenergic receptor.
  • beta-2 adrenoreceptor agonists are known in the art and include salmeterol, fenoterol and isoproterenol.
  • administering includes dispensing, delivering or applying an active compound in a pharmaceutical formulation to a subject by any suitable route for delivery of the active compound to the desired location in the subject, including delivery by either the parenteral or oral route, intramuscular injection, subcutaneous/intradermal injection, intravenous injection, buccal administration, transdermal delivery and administration by the rectal, colonic, vaginal, intranasal or respiratory tract route.
  • the language "contacting” is intended to include both in vivo or in vitro methods of bringing a compound of the invention into proximity with a neuron such that the compound can exert a neurosalutary effect on the neuron.
  • the term "effective amount" includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result, such as sufficient to produce a neurosalutary effect in a subject.
  • An effective amount of an active compound as defined herein may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the active compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects of the active compound are outweighed by the therapeutically beneficial effects.
  • a therapeutically effective amount or dosage of an active may range from about 0.001 to 30 mg kg body weight, with other ranges of the invention including about 0.01 to 25 mg/kg body weight, about 0.1 to 20 mg/kg body weight, about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg kg, 4 to 7 mg/kg, and 5 to 6 mg kg body weight.
  • the skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present.
  • treatment of a subject with a therapeutically effective amount of an active compound can include a single treatment or a series of treatments.
  • a subject is treated with an active compound in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, alternatively between 2 to 8 weeks, between about 3 to 7 weeks, or for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of an active compound used for treatment may increase or decrease over the course of a particular treatment.
  • subject is intended to include animals.
  • the subject is a mammal, a human or nonhuman primate, a dog, a cat, a horse, a cow or a rodent.
  • Neurological disorder is intended to include a disease, disorder, or condition that directly or indirectly affects the normal functioning or anatomy of a subject's nervous system.
  • Elements of the nervous system subject to disorders that may be effectively treated with the compounds and methods of the invention include the central, peripheral, somatic, autonomic, sympathetic and parasympathetic components of the nervous system, neurosensory tissues within the eye, ear, nose, mouth or other organs, as well as glial tissues associated with neuronal cells and structures.
  • Neurological disorders may be caused by an injury to a neuron, such as a mechanical injury or an injury due to a toxic compound, by the abnormal growth or development of a neuron, or by the misregulation (such as downregulation or upregulation) of an activity of a neuron.
  • Neurological disorders can detrimentally affect nervous system functions such as the sensory function (the ability to sense changes within the body and the outside environment); the integrative function (the ability to interpret the changes); and the motor function (the ability to respond to the interpretation by initiating an action such as a muscular contraction or glandular secretion).
  • nervous system functions such as the sensory function (the ability to sense changes within the body and the outside environment); the integrative function (the ability to interpret the changes); and the motor function (the ability to respond to the interpretation by initiating an action such as a muscular contraction or glandular secretion).
  • Examples of neurological disorders include traumatic or toxic injuries to peripheral or cranial nerves, spinal cord or to the brain, cranial nerves, traumatic brain injury, stroke, cerebral aneurism, and spinal cord injury.
  • neurological disorders include cognitive and neurodegenerative disorders such as Alzheimer's disease, dementias related to Alzheimer's disease (such as Pick's disease), Parkinson's and other Lewy diffuse body diseases, senile dementia, Huntington's disease, Gilles de la Tourette's syndrome, multiple sclerosis, amyotrophic lateral sclerosis, hereditary motor and sensory neuropathy (Charcot-Marie-Tooth disease), diabetic neuropathy, progressive supranuclear palsy, epilepsy, and Jakob- Creutzfieldt disease. Autonomic function disorders include hypertension and sleep disorders.
  • neuropsychiatric disorders such as depression, schizophrenia, schizoaffective disorder, Korsakoff s psychosis, mania, anxiety disorders, or phobic disorders, learning or memory disorders (such as amnesia and age-related memory loss), attention deficit disorder, dysthymic disorder, major depressive disorder, mania, obsessive-compulsive disorder, psychoactive substance use disorders, anxiety, phobias, panic disorder, bipolar affective disorder, psychogenic pain syndromes, and eating disorders.
  • neurological disorders include injuries to the nervous system due to an infectious disease (such as meningitis, high fevers of various etiologies, HIV, syphilis, or post- polio syndrome) and injuries to the nervous system due to electricity (including contact with electricity or lightning, and complications from electro-convulsive psychiatric therapy).
  • infectious disease such as meningitis, high fevers of various etiologies, HIV, syphilis, or post- polio syndrome
  • injuries to the nervous system due to electricity including contact with electricity or lightning, and complications from electro-convulsive psychiatric therapy.
  • the developing brain is a target for neurotoxicity in the developing central nervous system through many stages of pregnancy as well as during infancy and early childhood, and the methods of the invention may be utilized in preventing or treating neurological deficits in embryos or fetuses in utero, in premature infants, or in children with need of such treatment, including those with neurological birth defects.
  • stroke is art recognized and is intended to include sudden diminution or loss of consciousness, sensation, and voluntary motion caused by rupture or obstruction (for example, by a blood clot) of an artery of the brain.
  • Traumatic brain injury is art recognized and is intended to include the condition in which, a traumatic blow to the head causes damage to the brain or connecting spinal cord, often without penetrating the skull.
  • the initial trauma can result in expanding hematoma, subarachnoid hemorrhage, cerebral edema, raised intracranial pressure, and cerebral hypoxia, that can, in turn, lead to severe secondary events due to low cerebral blood flow.
  • compositions and packaged formulations comprising a neurotrophic factor of the invention and a pharmaceutically acceptable carrier are also provided by the invention. These pharmaceutical compositions may also include a macrophage-derived factor and/or a cAMP modulator.
  • the neurotrophic factor can be administered in a pharmaceutically acceptable formulation.
  • Such pharmaceutically acceptable formulation may include AF-1 as well as one or more pharmaceutically acceptable carriers and/or excipients.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and anti fungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • the carrier can be suitable for injection into the cerebrospinal fluid.
  • Excipients include pharmaceutically acceptable stabilizers and disintegrants.
  • the present invention pertains to any pharmaceutically acceptable formulations, including synthetic or natural polymers in the form of macromolecular complexes, nanocapsules, microspheres, or beads, and lipid-based formulations including oil-in-water emulsions, micelles, mixed micelles, synthetic membrane vesicles, and resealed erythrocytes.
  • the pharmaceutically acceptable formulations comprise a polymeric matrix.
  • polymer or “polymeric” are art-recognized and include a structural framework comprised of repeating monomer units that is capable of delivering a macrophage-derived factor such that treatment of a targeted condition, such as a neurological disorder, occurs.
  • the terms also include co-polymers and homopolymers such as synthetic or naturally occurring. Linear polymers, branched polymers, and cross-linked polymers are also meant to be included.
  • the active therapeutic compound can be encapsulated in one or more pharmaceutically acceptable polymers, to form a microcapsule, microsphere, or microparticle, terms used herein interchangeably.
  • the pharmaceutically acceptable formulations comprise lipid-based formulations. Prior to introduction, the formulations can be sterilized, by any of the numerous available techniques of the art, such as with gamma radiation or electron beam sterilization.
  • the pharmaceutically acceptable formulations of the invention are administered such that the active compound comes into contact with a subject's nervous system to produce a neurosalutary effect. Both local and systemic administration of the formulations are contemplated by the invention. Desirable features of local administration include achieving effective local concentrations of the active compound as well as avoiding adverse side effects from systemic administration of the active compound.
  • the active compound is administered by introduction into the cerebrospinal fluid of the subject.
  • the active compound is introduced into a cerebral ventricle, the lumbar area, or the cisterna magna.
  • the active compound is introduced locally, such as into the site of nerve or cord injury, into a site of pain or neural degeneration, or intraocularly to contact neuroretinal cells.
  • the pharmaceutically acceptable formulations can be suspended in aqueous vehicles and introduced through conventional hypodermic needles or using infusion pumps.
  • the active compound formulation is administered into a subject intrathecally.
  • intrathecal administration is intended to include delivering an active compound formulation directly into the cerebrospinal fluid of a subject, by techniques including lateral cerebroventricular injection through a burrhole or cisternal or lumbar puncture or the like (described in Lazorthes et al. Advances in Drug Delivery Systems and Applications in Neurosurgery, 143-192 and Omaya et al. Cancer Drug Delivery, 1 : 169-179, the contents of which are incorporated herein by reference).
  • lumbar region is intended to include the area between the third and fourth lumbar (lower back) vertebrae.
  • cisterna magna is intended to include the area where the skull ends and the spinal cord begins at the back of the head.
  • Cerebral ventricle is intended to include the cavities in the brain that are continuous with the central canal of the spinal cord.
  • Administration of an active compound to any of the above mentioned sites can be achieved by direct injection of the active compound formulation or by the use of infusion pumps. Implantable or external pumps and catheter may be used.
  • the active compound formulation of the invention can be formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution.
  • the active compound formulation may be formulated in solid form and re-dissolved or suspended immediately prior to use. Lyophilized forms are also included.
  • the injection can be, for example, in the form of a bolus injection or continuous infusion (such as using infusion pumps) of the active compound formulation.
  • the active compound formulation may be administered by injection or through a surgically inserted shunt into a subject's cerebral ventricle, such as the lateral, third or fourth ventricle, or into the cisterna magna or the lumbar area of a subject.
  • An additional means of administration to intracranial tissue involves application of compounds of the invention to the olfactory epithelium, with subsequent transmission to the olfactory bulb and transport to more proximal portions of the brain.
  • Such administration can be by nebulized or aerosolized preparations.
  • the active compound formulation is administered to a subject at a site of neurological injury.
  • the active compound formulation described herein is administered to the subject in the period from the time of a neural system injury or appearance of neurological symptoms up to about 100 hours after the injury has occurred.
  • AF-1 can be used in conjunction with other compounds used to treat neurological disorders or conditions.
  • AF-1 may be used in conjunction with a PARS inhibitor (see, for example, published patent application WOO 142219 to Inotek), an interferon, human transforming growth factor (TGF) beta-2-cyclophosphamide glatiramer acetate (also known as Cop- 1 or copolymer- 1), azathloprine, corticosterolds such as methylprednisolone given intravenously or oral prednisone, immunoblobulins or one or more immunosuppressant treatments.
  • TGF human transforming growth factor
  • TGF human transforming growth factor beta-2-cyclophosphamide glatiramer acetate
  • azathloprine also known as Cop- 1 or copolymer- 1
  • corticosterolds such as methylprednisolone given intravenously or oral prednisone
  • immunoblobulins or one or more immunosuppressant treatments can
  • immunosuppressant agents or procedures can include total lymphoid irradiation, cladribine. mitoxantrone. sulfasalazine. cyclosporine. acyclovir, and oral bovine myelin.
  • AF-1 may be administered in conjunction with antibodies that block growth-inhibiting proteins on the surface of CNS oligodendrocytes, as well as with agents that prevent free radical formation, such as LaZaroid, a 21-aminosteriod, or free radical scavengers such as phenylbutylnitrone and derivatives.
  • the active compound is administered to a subject for an extended period of time to produce a neurosalutary effect.
  • Sustained contact with the active compound can be achieved by, for example, repeated administration of the active compound over a period of time, such as one week, several weeks, one month or longer.
  • the pharmaceutically acceptable formulation used to administer the active compound provides sustained delivery, such as "slow release" of the active compound to a subject.
  • the formulation may deliver the active compound for at least one, two, three, or four weeks after the pharmaceutically acceptable formulation is administered to the subject.
  • a subject to be treated in accordance with the present invention is treated with the active compound for at least 30 days (either by repeated administration or by use of a sustained delivery system, or both).
  • sustained delivery is intended to include continual delivery of the active compound in vivo over a period of time following administration, preferably at least several days, a week, several weeks, one month or longer.
  • Sustained delivery of the active compound can be demonstrated by, for example, the continued therapeutic effect of the active compound over time (such as sustained delivery of the macrophage-derived factor can be demonstrated by continued production of a neurosalutary effect in a subject).
  • sustained delivery of the active compound may be demonstrated by detecting the presence of the active compound in vivo over time.
  • Preferred approaches for sustained delivery include use of a polymeric capsule, a minipump to deliver the formulation, bioerodible implant, or implanted transgenic autologous cells (as described in U.S. Patent No. 6,214,622).
  • Implantable infusion pump systems such as Infusaid; see such as Zierski, J. et al. (1988) Acta Neurochem. Suppl. 43:94-99; Kanoff, R.B. (1994) J. Am. Osteopath. Assoc. 94:487-493
  • osmotic pumps are available in the art.
  • Another mode of administration is via an implantable, externally programmable infusion pump.
  • Suitable infusion pump systems and reservoir systems are also described in U.S. Patent No. 5, 368,562 by Blomquist and U.S. Patent No. 4,731,058 by Doan, developed by Pharmacia Deltec Inc.
  • dosage values may vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the active compound and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed invention.
  • the invention in another embodiment, provides a pharmaceutical composition consisting essentially of an AF-1 compositions and a pharmaceutically acceptable carrier, as well as methods of use thereof to effect neurosalutatory changes by contacting neurons with the composition.
  • the pharmaceutical composition of the invention can be provided as a packaged formulation.
  • the packaged formulation may include a pharmaceutical composition of the invention in a container and printed instructions for administration of the composition for producing a neurosalutary effect in a subject having a neurological disorder.
  • Use of a macrophage- derived factor in the manufacture of a medicament for effecting a neurosalutatory change of neurons is also encompassed by the invention.
  • Neurons derived from the central or peripheral nervous system can be contacted with a neurotrophic factor such as AF-1 (alone or in combination with a macrophage- derived factor and/or a cAMP modulator) in vitro to modulate axonal outgrowth.
  • a neurotrophic factor such as AF-1 (alone or in combination with a macrophage- derived factor and/or a cAMP modulator) in vitro to modulate axonal outgrowth.
  • AF-1 alone or in combination with a macrophage- derived factor and/or a cAMP modulator
  • neurons can be isolated from a subject and grown in vitro, using techniques well known in the art, and then treated in accordance with the present invention to effect neurosalutatory changes, such as maintaining normal cellular architecture or chemical composition, promoting cellular survival, or enhancing neurocellular regeneration as evidenced by increasing GAP-43 expression or stimulating axonal outgrowth.
  • a neuronal culture can be obtained by allowing neurons to migrate out of fragments of neural tissue adhering to a suitable substrate (such as a culture dish), or by producing a suspension of neurons by disaggregating the tissue using mechanical, enzymatic or other means.
  • the enzymes trypsin, collagenase, elastase, hyaluronidase, DNase, pronase, dispase, or various combinations thereof can be used.
  • Methods for isolating neuronal tissue and the disaggregation of tissue to obtain isolated cells are described in Freshney, Culture of Animal Cells: A Manual of Basic Technique, Third Ed. 1994, the contents of which are incorporated herein by reference.
  • Such cells can be subsequently contacted with an AF-1 neurotrophic factor in amounts and for a duration of time as described above. Once neurosalutatory changes been achieved in the neurons, these cells can be re-administered to the subject, such as by implantation.
  • Example 1 Development of model to identify endogenous neurotrophic factors.
  • conditioned medium conditioned medium
  • dissociated retinal cultures Animals were anesthetized by chilling to 4°C and then sacrificed by cervical transection. Optic nerves and tracts were dissected free of bone and connective tissue in two stages: a gross dissection under 2X magnification to yield optic nerves and tracts freed from the eyes and optic tecta but with some connective tissue and bone still attached, then a second stage carried out under 12X magnification using a table-top dissecting microscope (Wild). Following procedures described by Schwartz et al. (1985) and modified by Finkelstein et al.
  • Medium E contains 20 nM hydrocortisone, 1 mM kainurinate, 100 ⁇ M putrescine, 20 nM progesterone, 30 nM selenium, 0.3 nM 3, 3'5-triiodo-L-thyronine, 50 ⁇ g/ml transferrin, 150 U/ml catalase, 60 U/ml superoxide dismutase, 1%> bovine serum albumin (Type V), 10 ⁇ g/ml gentamicin, 5 ⁇ g/ml insulin, and 15 mM HEPES (all reagents from Sigma). Medium E was titrated to pH 7.4 and filter-sterilized prior to being added to culture plates.
  • each well received 50 pi of cell suspension, then the experimental or control sample brought up to 150 pi with L-15. Except where noted otherwise, experimental samples were set up in a blinded, randomized fashion by another member of the lab so that the investigator was unaware of the conditions present in any well.
  • each experimental condition was represented in 4 to 8 wells; every experiment also included at least 4 wells of a positive control (of previously validated conditioned medium at a 5 to 15% concentration) and at least 4 wells of an L-15 and Medium E alone as a negative control.
  • CFDA 5,6-carboxyfluorescein diacetate
  • PBS phosphate-buffered saline
  • CFDA a vital dye
  • Cultures were examined at lOOx magnification under fluorescent illumination (Nikon AF-BS inverted microscope) using a green barrier filter. The total number of viable cells in fourteen consecutive microscope frames (i.e., single well radii) was recorded starting at the top of the well.
  • RRCs retinal ganglion cells
  • Example 2 Determination of source of tropic factors.
  • Cytosol fractions were prepared by homogenizing 10 optic nerves in 25 mM HEPES, pH 7.4 or L-15. The high-speed supernatant of this extract was matched for protein concentration to whole conditioned medium using the BioRadTM protein assay. The optic nerve cytosol and conditioned medium were then separated into high and low molecular weight fractions with a Centriprep-3TM filter. Fractions were screened in the bioassay.
  • the factors were also examined to determine if they were secreted selectively by the optic nerve by comparing standard conditioned medium with media conditioned with factors secreted by other goldfish tissues.
  • the optic nerves required to prepare 3 ml of conditioned medium were weighed prior to mincing. Equal masses of tissue from goldfish skeletal muscle, liver, and gill were used to prepare conditioned media as described above.
  • taurine at concentrations of 10-9 to 10-3 M (Sigma), retinoic acid (10-9 to 104 M: Sigma), and NGF ( ⁇ -subunit, 100 nM: Collaborative Research, Bedford, MA) were tested in the bioassay. Additional experiments were carried out to examine whether the response of RGCs to conditioned medium depended on the density of plating in culture. In addition to the standard cell density used throughout the studies, the cells were also plated at 1/3, 1/9 and 1/27 of this density.
  • Dissociated retinal cells respond to factors derived from the optic nerve.
  • the response of dissociated retinal cells to factors secreted by the optic nerve was determined using the dye 5,6-CFDA. Under baseline conditions, cells remain viable but show little outgrowth. With the addition of conditioned medium containing factors secreted by the optic nerve, cells 10-17 ⁇ m across extend one or two long processes of a uniformly thin caliber that sometime terminate in a prominent growth cone. Larger, polygonal cells are not counted in quantifying neurite outgrowth.
  • Figure la is a histogram of axon length distribution 5 days after being cultured with conditioned medium at the indicated concentrations. Although the number of cells extending processes 1 to five cell diameter in length changes little with increasing concentrations of conditioned medium, the number extending processes greater than five cell diameter in length increases greatly.
  • Figure lb depicts dose-response curves of two separate experiments showing neurite outgrowth in response to increasing concentrations of conditioned medium. Data represent the percentage of cells with processes greater than five cell diameter in length, a cut-off point selected based upon the histogram date in Figure la.
  • Figure lc is a graph of cell survival as a function of conditioned medium concentration in two independent experiments.
  • Figure lb shows the dose-response curves of two consecutive experiments using different preparations of conditioned medium and retinas.
  • conditioned medium concentrations up to 10% the number of cells with axons greater than five cell diameters in length increases, then levels off (outgrowth in response to 5% conditioned medium vs. L-15 + Medium E alone, p ⁇ 0.001 for both experiments; growth with 10% conditioned medium vs. 5% conditioned medium, p ⁇ 0.02 for both; error bars not shown if less than 1%>; one of these 2 experiments was carried out early in the study and was not blinded).
  • the maximum number of cells responding differs somewhat between the two experiments, perhaps reflecting differences in the percentage of RGCs in the two preparations.
  • the inset demonstrates that conditioned medium has little effect on cell viability.
  • Retrograde labeling was used to investigate outgrowth in retinal ganglion cells per se.
  • Application of 4-Di-10 ASP to a small region of the optic tectum resulted in the retrograde labeling of 4-5%> of the viable cells in culture. These cells were ellipsoid, measuring 8-10 x 16-18 ⁇ m, similar to the dimensions of RGCs reported by Schwartz & Agranoff (1981) Brain Res. 206:331-343.
  • the cells labeled with 4-di-10 ASP showed little spontaneous outgrowth in the presence of L-15 and Medium E alone; in response to 10% conditioned medium, however, these cells showed twice the level of neurite outgrowth observed in the overall cell population. The survival of RGCs is unaffected by conditioned medium.
  • the number of retrograde labeled cells in culture was 4 to 5% irrespective of the presence or absence of conditioned medium.
  • p ⁇ 0.005 for both sets of retinas.
  • Retinal ganglion cells were labeled by applying the lipophilic dye 4-di- 10 ASP to the optic tectum 7 days prior to culturing. After 6 days in culture, labeled cells extended one or two processes in response to conditioned medium. These cells generally formed one or two long, thin processes. For both sets of retinas, the viability of retrograde labeled cells relative to the overall cell population showed no change with the addition of conditioned medium. Thus, conditioned medium stimulates neurite outgrowth from RGCs selectively, and this effect is not a consequence of enhancing the survival of this cell type. This study also provides criteria (diameter, number of processes) for distinguishing the ganglion cells in the mixed, 5,6-CFDA-stained cultures.
  • media conditioned by an equal mass of goldfish skeletal muscle, gill, or liver showed little neurite-promoting activity (all samples differ from optic nerve conditioned medium at p ⁇ O.Ol; experiment not blinded).
  • Example 3 Isolation and characterization of neurotropic factors.
  • Optic Nerve Conditioned Medium Contains Two Trophic Factors.
  • conditioned media was prepared from optic nerves dissected either from normal goldfish or from animals 3 or 7 days after bilateral optic nerve crush, then used ultrafiltration to separate the conditioned medium samples into fractions less than 3,000 Da and greater than 3,000 Da in size.
  • Conditioned medium obtained from either intact or injured optic nerves yielded both high and low molecular weight neurite-promoting factors (all samples show higher growth than the L-15 control at a level of p ⁇ 0.002).
  • data have been represented by first subtracting the level of growth in negative controls grown with Medium E and L-15 alone (3 + 0.2% [mean + S.E.M.] in this particular experiment), then normalizing by the net growth in positive controls treated with unfractionated conditioned medium (21.3 + 2.3% in this instance).
  • Conditioned medium was first separated by centrifugal ultrafiltration using filters with molecular weight cut-offs of 10, 100, and 1000 kDa (Amicon, Beverly, MA). Filtrates and retentates were tested in the bioassay. Next, conditioned medium was passed through a 6 kDa desalting column (BioRad) and fractions were monitored by absorbance at 280 nm (for protein) and by measuring conductivity (for low-molecular weight fractions containing salts). Fractions containing high and low molecular weight constituents were evaluated by bioassay and were both found to be active, as shown in Figure 2a.
  • the low molecular weight material (less than 6 kDa) was characterized further by being passed through a Centriprep-3 ⁇ filter (Amicon) or a MicrosepTM (Filtron, Northborough, MA) centrifugal filter with a 1 kDa cut-off.
  • Bound proteins were then eluted with successive 3 ml steps of 0.1, 0.2, 0.5 and 1.0 M NaCl in 25 mM HEPES. Fractions were divided into aliquots and stored at -80°C for bioassays. Ion-exchange chromatography was also carried out on the high molecular weight fraction of conditioned medium at pH 10.
  • the Smaller Trophic Factor Passes Through a 1 , 000 Da Filter.
  • Figure 2c shows the elution profile of the high molecular weight fraction of conditioned medium when separated by size-exclusion HPLC.
  • the active factor has a similar retention time as cytochrome C (12 kDa; Figure 2d), so the size is estimated to be in the range of between 8,000 and 15,000 Da. In some experiments, an additional peak of activity has been observed at 70 to 100 kDa, but this has not been reproducible. This larger molecule may be unstable and degrade to form the 12,000 Da factor, or it may be a multimeric complex that dissociates under certain experimental conditions.
  • Ion-exchange chromatography was used to purify the larger factor further. Separation of the high molecular weight component of conditioned medium by DEAE-anion-exchange chromatography was performed. At pH 8.4, neurite-promoting activity was recovered in the unbound fraction, whereas at pH 10, the active factor bound to the column and eluted with 0.2 M NaCl. Neither component of conditioned medium acts as a substrate-bound trophic factor. Conditioned medium was separated into high and low molecular weight fractions by ultrafiltration (3,000 Da cut-off). Prolonged exposure of the larger protein to elevated pH appears to reduce its activity significantly.
  • Polylysine-coated plates were incubated overnight with either the high or low molecular weight fractions of conditioned medium, either at full-strength or at a 1 :10 dilution. After rinsing wells to remove unbound material, no neurite-promoting activity . was retained after rinsing plates with L-15. Thus, neither the large nor the small factor acts as a substrate-bound growth factor.
  • Figure 3 is a graph of neurite outgrowth showing that the low molecular weight factor, AF-1, can be isolated using a two-phase solvent extraction system.
  • the negative control is culture medium alone; the positive control, lane 2, is the low molecular weight fractions of the molecules secreted by the glial sheath cells into culture medium, conditioned medium less than 3,000 Da that induces high levels of axonal growth.
  • this material is mixed with an organic solvent at pH 7.5, isobutanol, little activity remains in the aqueous phase (pH 7.5 Aq).
  • the organic phase is then mixed with a low pH buffer (pH2 Aq)
  • the biologically active molecule goes into the aqueous phase and nothing remains in the organic phase, (pH2 org). This provides a simple method for the initial purification of the low molecular weight trophic factor AF-1.
  • Figure 4 is a graph of neurite outgrowth showing that when the partially purified extract containing the low molecular weight trophic factor, AF-1, is separated by reversed phase HPLC, the active component appears in the column fractions designated FC, FD, and FE.
  • the negative control L-15
  • the positive control is the unfractionated low molecular weight component of the molecules secreted by optic nerve glia (conditioned medium less than 3,000 Da, 10%) concentration);
  • FA-FI indicate column fractions from the high performance liquid chromatography separation.
  • Whether the two neurite-promoting factors are actively secreted was then determined by comparing their activity in conditioned medium and in the high-speed supernatant fraction of optic nerve homogenates. Samples were used in the bioassay at concentrations of 10% and 20%, adjusting the protein concentration of the optic nerve cytosol to match that of the conditioned medium (i.e., a 10%) concentration is equivalent to a protein concentration prior to ultrafiltration of about 10 ⁇ g/ml protein for each. This is based on the hypothesis that most of the proteins found in conditioned medium arise from cell lysis and not by active secretion).
  • retinas were plated at either the standard density used throughout, these studies (about 70 cells/mm2) or at increasingly lower densities. If RGCs are responding to a secondary factor released by another type of cell that is the direct target of conditioned medium, then as the number of these other cells decrease and the concentration of a secondary factor decreases, one would expect to find a diminished response of RGCs at lower cell densities.
  • Retinas dissected from either previously intact fish or fish that had undergone optic nerve surgery 14 days previously to initiate the regenerative response were dissociated and cultured in the presence of either control (L-15) medium alone, unfractionated conditioned medium at a 10%) concentration, or the low molecular weight fraction of conditioned medium at a 10%) concentration.
  • control (L-15) medium alone unfractionated conditioned medium at a 10%) concentration
  • the low molecular weight fraction of conditioned medium at a 10%) concentration was unaffected by the 'priming' lesion. This was done to determine whether the neurite-promoting factors in conditioned medium would allow 'naive' retinal ganglion cells to grow to the same extent as 'primed' cells in which the regenerative process had been initiated in vivo.
  • taurine in the presence of laminin, augments neurite outgrowth from retinal explants primed to regenerate in vivo, but has little effect on previously intact retina. Taurine also contributes to the differentiation of rod cells (Altffler et al. (1993) Development, 119:1317-1328). In this cell system, taurine, at concentrations between 1 ⁇ m and 10 mM, had no effect at all, nor did retinoic acid at concentrations between 10 ⁇ 9 and 10"4.
  • Retinoic acid RA
  • RA Retinoic acid
  • NGF nerve growth factor
  • NGF 5 ng/ml
  • the ⁇ -subunit of mammalian NGF augments neurite outgrowth from goldfish retinal explants that had been primed to grow in vivo, while antibodies to NGF suppress outgrowth from primed retinal explants maintained in the presence of serum (Turner et al. 1982).
  • NGF has little effect on explants of unprimed retina (turner et al. 1982) or on the rate of axonal outgrowth in vivo (Yip & Grafstein, 1982).
  • NGF may stimulate glial cells to release factors that in turn act upon neurons.
  • AF-1 can each induce neurite outgrowth independently in these assays, and their effects do not appear to be synergistic. Nevertheless, it is possible that in vivo they function in a complementary fashion. It is also possible that AF-1 derives from degradation of AF-2. Since the cultures contain a variety of cell types, it remains possible that AF-1 may not act directly upon retinal ganglion cells, but rather upon another cell type as an intermediary. As observed by Schwartz & Agranoff (1981), RGCs are the dominant cell type in dissociated goldfish retinal cultures prepared as described above, and support cells are not abundant.
  • cell density was systematically reduced to decrease the concentration of any secondary factors that might be released by another cell type while holding the concentration of conditioned medium constant. Since neurite outgrowth did not decline significantly over a 9-fold decrease in cell density, the RGCs would appear to be responding to conditioned medium directly. At a cell density of c. 3 cells/mm ⁇ , however, outgrowth did show a significant decline. This could result from a decreased concentration of a trophic factor, released from another cell type in culture or from RGCs themselves, this is required to maintain the cells in a state in which they can respond to conditioned medium.
  • rat Schwann cells derived from postnatal sciatic nerves, were grown to confluence in the presence of a pituitary-derived factor using the method of Brockes (1979) Brain Res.165 (1): 105-18. Cells were rinsed three times and incubated in saline for 1-2 hours. Conditioned media, containing factors secreted by Schwann cells, were passed through ultrafiltration devices with molecular weight cutoffs of 3 and 1 kilodaltons. Biological activity of the mammalian AF-1 was examined using our standard bioassay, e.g., axonal outgrowth from dissociated goldfish retinal ganglion cells.
  • the mammalian AF-1 is readily extracted into 95% ethanol, after being lyophilized, thereby readily separating it from inorganics.
  • Other properties established for mammalian AF-1 are that it fails to bind to a C18 reversed-phase HPLC column, that on a GlO-Sepharose size-exclusive column, it has a characteristic elution time, and that after being chemically derivatized with AQC it forms a compound that elutes from a reverse-phase HPLC column at 23 minutes.
  • AF-1 was applied to the uninjured side of the brain via a minipump for 2 weeks, after which the trajectories of new axons were investigated using the anterograde tracer biotin dextran amine (BDA).
  • BDA biotin dextran amine
  • Mammalian AF- 1 induced even more axon growth than inosine.
  • AF-1 caused numerous axon branches to grow from the intact CST over to the denervated side. It is likely that these new axons form functional connections (synapses) in the appropriate region on the denervated side, since varicosities were observe that resemble synaptic endings in the correct lamina of the spinal cord.
  • vitreous fluid from the eye of a cow was used. Briefly, vitreous fluid was extracted from the bovine eye and diluted in saline (3:1 saline:vitreous fluid). High molecular weight components were separated out using ultrafiltration (and a membrane of a 1 kDa cut-off) and the low-molecular weight filtrate was lyophilized. AF-1 was extracted into acetonitrile (CAN: in ratio of 10 ml CAN: 1 ml diluted vitreous fluid) and the soluble fraction was dried by speed- vac. The lyophilized ACN extract was solubilized in acetonitrile (3:1 acetonitrile:water; vol. ⁇ 0.5 ml) and the sample was applied to a normal-phase LC-NH 2 column. The resulting elution profile is shown in Figure 5 A.
  • vitreous fluid of newborn calves is a rich source of AF-1.
  • Molecules in the vitreous fluid are extracted into saline (4:1 dilution) at 4°C.
  • the saline extract (BV 1 :4) is passed through a lkDa molecular weight cut-off filter to remove components >1 kDa.
  • the low molecular weight fraction is then lyophilized, and concentrated approximately 30:1 by redissolving in a small volume of water.
  • This sample is then chromatographed on a SephadexTM-G10 column attached to an HPLC instrument, and the eluted material is monitored at 214 nm and 280 nm.
  • Fractions are then bioassayed using our standard dissociated goldfish retinal ganglion cell cultures (described in Schwalb et al., 1995).
  • the fractions containing the axon-promoting activity are then re-pooled and separated again on the same column to purify the axon-promoting activity further.
  • This material is then applied to a LC-NH 2 column (normal-phase), using as a mobile phase 75%> acetonitrile in water. From our previous studies, AF-1 was found to elute with a long retention time, thereby separating it from most other components of the BV. Combining the two columns (G10 SepharoseTM and LC-NH 2 yields a highly enriched AF-1.
  • This material is then analyzed by mass-spectrometry (MS-MS) to identify the structure of the components present.
  • MS-MS mass-spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés présents dans des milieux conditionnés par une cellule de Schwann, des compositions et des procédés utiles pour traiter des états neurologiques.
PCT/US2001/022315 2000-07-14 2001-07-16 Facteur tropique capable de produire un effet salutaire sur le systeme nerveux chez un sujet WO2002006341A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001280566A AU2001280566A1 (en) 2000-07-14 2001-07-16 A trophic factor capable of producing a neurosalutary effect in a subject

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61628700A 2000-07-14 2000-07-14
US09/616,287 2000-07-14

Publications (1)

Publication Number Publication Date
WO2002006341A1 true WO2002006341A1 (fr) 2002-01-24

Family

ID=24468798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022315 WO2002006341A1 (fr) 2000-07-14 2001-07-16 Facteur tropique capable de produire un effet salutaire sur le systeme nerveux chez un sujet

Country Status (2)

Country Link
AU (1) AU2001280566A1 (fr)
WO (1) WO2002006341A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1542702A2 (fr) * 2002-09-27 2005-06-22 Children's Medical Center Corporation Procedes et compositions pour le traitement des troubles neurologiques
WO2007133749A2 (fr) * 2006-05-12 2007-11-22 Children's Medical Center Corporation Méthodes et compositions pour traiter et prévenir une lésion d'un nerf périphérique
US8545099B2 (en) 2008-03-06 2013-10-01 Sonoco Development, Inc. Flexible packaging structure with built-in tamper-evidence features and method for making same
CN103751845A (zh) * 2014-01-30 2014-04-30 中国人民解放军海军总医院 一种用于移植修复周围神经缺损的组织工程生物材料

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017818A1 (fr) * 1993-02-08 1994-08-18 The Syntex-Synergen Neuroscience Joint Venture Procedes permettant le traitement de la sclerose laterale amyotrophique avec le cntf
WO1996006859A1 (fr) * 1994-08-26 1996-03-07 Children's Medical Center Corporation Thromboplastines tissulaires destinees a la regeneration du systeme nerveux central
WO1996013518A1 (fr) * 1994-10-27 1996-05-09 Genentech, Inc. Facteur neurotrophique al-1, un ligand pour le recepteur tyrosine kinase apparente a eph
WO1998032869A1 (fr) * 1997-01-29 1998-07-30 Neurosearch A/S Vecteurs d'expression et procedes d'expression in vivo de polypeptides therapeutiques
WO1999015191A2 (fr) * 1997-09-19 1999-04-01 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Cytokines ayant une activite neurotrophique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017818A1 (fr) * 1993-02-08 1994-08-18 The Syntex-Synergen Neuroscience Joint Venture Procedes permettant le traitement de la sclerose laterale amyotrophique avec le cntf
WO1996006859A1 (fr) * 1994-08-26 1996-03-07 Children's Medical Center Corporation Thromboplastines tissulaires destinees a la regeneration du systeme nerveux central
WO1996013518A1 (fr) * 1994-10-27 1996-05-09 Genentech, Inc. Facteur neurotrophique al-1, un ligand pour le recepteur tyrosine kinase apparente a eph
WO1998032869A1 (fr) * 1997-01-29 1998-07-30 Neurosearch A/S Vecteurs d'expression et procedes d'expression in vivo de polypeptides therapeutiques
WO1999015191A2 (fr) * 1997-09-19 1999-04-01 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Cytokines ayant une activite neurotrophique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BASSAN M ET AL.: "Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide", JOURNAL OF NEUROCHEMISTRY., vol. 72, 1999, NEW YORK, NY, US, pages 1283 - 1293, XP000882112, ISSN: 0022-3042 *
HANSON M G JR ET AL.: "Cyclic AMP elevation is sufficient to promote the survival of spinal motor neurons in vitro", JOURNAL OF NEUROSCIENCE, vol. 18, no. 18, 15 September 1998 (1998-09-15), NEW YORK, NY, US, pages 7361 - 7371, XP001031490, ISSN: 0270-6474 *
SCHWALB ET AL.: "Optic nerve glia secrete a low-molecular -weight factor that stimulates retinal ganglion cells to regenerate axons in goldfish", NEUROSCIENCE, vol. 72, no. 4, 1996, NEW YORK, NY, US, pages 901 - 910, XP001031288, ISSN: 0306-4522 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1542702A2 (fr) * 2002-09-27 2005-06-22 Children's Medical Center Corporation Procedes et compositions pour le traitement des troubles neurologiques
EP1542702A4 (fr) * 2002-09-27 2008-08-27 Childrens Medical Center Procedes et compositions pour le traitement des troubles neurologiques
WO2007133749A2 (fr) * 2006-05-12 2007-11-22 Children's Medical Center Corporation Méthodes et compositions pour traiter et prévenir une lésion d'un nerf périphérique
WO2007133749A3 (fr) * 2006-05-12 2008-04-17 Childrens Medical Center Méthodes et compositions pour traiter et prévenir une lésion d'un nerf périphérique
US8545099B2 (en) 2008-03-06 2013-10-01 Sonoco Development, Inc. Flexible packaging structure with built-in tamper-evidence features and method for making same
CN103751845A (zh) * 2014-01-30 2014-04-30 中国人民解放军海军总医院 一种用于移植修复周围神经缺损的组织工程生物材料

Also Published As

Publication number Publication date
AU2001280566A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
RU2157223C2 (ru) Трофические факторы для регенерации центральной нервной системы
Piri et al. Heat shock proteins in the retina: focus on HSP70 and alpha crystallins in ganglion cell survival
Kole et al. Activating transcription factor 3 (ATF3) protects retinal ganglion cells and promotes functional preservation after optic nerve crush
Yaar et al. Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease.
Azmitia et al. S-100B but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth factor
Thanos et al. Role of crystallins in ocular neuroprotection and axonal regeneration
Tönges et al. Hepatocyte growth factor protects retinal ganglion cells by increasing neuronal survival and axonal regeneration in vitro and in vivo
Schwalb et al. Two factors secreted by the goldfish optic nerve induce retinal ganglion cells to regenerate axons in culture
WO1996006859A9 (fr) Thromboplastines tissulaires destinees a la regeneration du systeme nerveux central
Hellweg et al. Neurotrophins-From pathophysiology to treatment in Alzheimer's disease
Lebrun-Julien et al. Molecular and cell-based approaches for neuroprotection in glaucoma
US6262024B1 (en) Neuron regulatory factor for promoting neuron survival
JP4943847B2 (ja) 抗分泌性因子の新規の使用
Schwalb et al. Optic nerve glia secrete a low-molecular-weight factor that stimulates retinal ganglion cells to regenerate axons in goldfish
AU675409B2 (en) Methods of treatment of motor neuron diseases using members of the BDNF/NT-3/NGF family of molecules
Tuszynski et al. Growth factor gene therapy for Alzheimer disease
JP2007514748A5 (fr)
Hisajima et al. Effects of acidic fibroblast growth factor on higpocampal long‐term potentiation in fasted rats
WO2002006341A1 (fr) Facteur tropique capable de produire un effet salutaire sur le systeme nerveux chez un sujet
Liu et al. Expression Pattern of Ngb in Astrocytes after Spinal Cord Injury and the Clinical Significance
US20090156496A1 (en) Methods and compositions for treating and preventing peripheral nerve damage
KR20120101390A (ko) Ｂｄｎｆ （뇌-유래 신경영양성 인자）에 기반한 안과용 조성물 및 그의 용도
US20080039380A1 (en) Agent for Prophylactic and/or Therapeutic Treatment of Retinopathy
Liu et al. Regulation of axonal regeneration following the central nervous system injury in adult mammalian
US20090291887A1 (en) Proteins of the SDF-1-Family for the Manufacturing of a Medicament

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载